Zonisamide is a new type of benzisoxazole derivative, first marketed in Japan in 1989. This study analyzed: (1) the drug's efficacy by seizure and epilepsy type in a total of 1008 patients treated during the development of zonisamide in Japan; (2) the effectiveness of zonisamide for 726 newly-diagnosed patients treated with zonisamide postmarketing; and (3) 50 patients with generalized epilepsies and epileptic syndromes (idiopathic generalized epilepsies, symptomatic generalized epilepsies, Lennox-Gastaut syndrome, Doose syndrome, and West syndrome), and 19 patients with undetermined epilepsies and specific syndromes (refractory grand mal in childhood, severe myoclonic epilepsy in infancy, other undetermined epilepsy, familial essential myoclonic epilepsy, and mitochondrial encephalomyopathy with ragged-red fibers). Analysis of study results showed that among all patients treated, zonisamide was highly effective for the treatment of idiopathic generalized epilepsy, temporal lobe epilepsy, and other partial epilepsies. The compound was also effective for other symptomatic generalized epilepsies. In 50 patients with generalized epilepsies, and 19 with undetermined epilepsies and specific syndromes, seizure frequency was reduced by >50% with monotherapy or two-drug therapy with zonisamide. Zonisamide was effective not only for partial epilepsies and generalized epilepsies but also for undetermined epilepsies and specific syndromes such as myoclonus epilepsy.
Introduction
Zonisamide is a benzisoxazole derivative, chemically unrelated to existing antiepileptic drugs (AEDs). 1 Zonisamide's mechanism of action is apparently based on its ability to block voltagesensitive sodium and T-type calcium channels. [2] [3] [4] In view of its potential as a broad-spectrum AED, zonisamide was studied extensively in pre-and postmarketing trials in Japan. Pooled efficacy data from 1008 patients in Phase II and III studies, 5 as well as data from a postmarketing study of 726 newly-diagnosed patients [internal report, Dainippon Pharmaceutical Company Ltd.], are presented in this paper. In addition, experience with the use of this agent in smaller patient cohorts at the National Epilepsy Center, Shizuoka, sheds further light on the efficacy of zonisamide.
Premarketing studies
Pooled efficacy data on 1008 patients from controlled and uncontrolled Phase II and III studies conducted over a 7-year period at 56 centers in Japan S12 K. Yagi were analyzed with respect to epilepsy and seizure type.
The efficacy rate was defined as the percentage of patients whose seizure frequency was reduced by 50% or more from baseline by adjunctive therapy with zonisamide in uncontrolled trials or compared with carbamazepine or valproate in controlled trials.
The age distribution of the patients and mean dose per group are shown in Table 1 . Fig. 1 shows the efficacy of zonisamide in relation to the number of concomitant AEDs. Of 55 patients treated with zonisamide alone, the efficacy rate was 72%. This dropped to 52, 48, and 43% in the patients treated with 1, 2, or 3 additional AEDs. These data suggest that the smaller the number of concomitant AEDs, the greater the efficacy of zonisamide. The concomitant AEDs were, in decreasing order of use, carbamazepine, phenytoin, valproic acid, phenobarbital, clonazepam, primidone, acetazolamide, nitrazepam, sulthiame, and ethosuximide.
Partial epilepsies accounted for nearly 70% of all epilepsy types in the population studied. Of 673 patients with partial epilepsy, 64% had temporal lobe epilepsy, 33% had non-temporal lobe epilepsy, and 3% had unclassified partial epilepsy. Efficacy rates ranged from 51 to 57% in patients with partial epilepsies as shown in Fig. 2 .
Among 282 patients with generalized epilepsies, efficacy rates ranged from 22 to 66% (Table 2) . Thus, zonisamide appeared to be effective not only for partial epilepsies, but also to some extent for generalized epilepsies.
Analysis of data by seizure type in 954 patients with identified seizures revealed that zonisamide was effective in all types of partial seizures, and to varying degrees in all types of generalized seizures (Table 3) . Partial seizures accounted for 70% of all seizure types. Data on the efficacy rates in relation to seizure frequency in 935 patients with identified seizure frequency show that the addition of zonisamide was effective in 42% of patients having daily seizures, as shown in Fig. 3 . The lower the seizure frequency, the higher the efficacy of zonisamide.
The most frequent adverse event associated with zonisamide therapy was drowsiness (24%), followed by ataxia (13%), loss of appetite (11%), gastrointestinal symptoms (7%), decrease of spontaneity (6%), and slowing of mental activity (5%).
Postmarketing experience
Zonisamide monotherapy in newly-diagnosed patients in a retrospective study One large postmarketing trial studied zonisamide monotherapy in 736 patients newly diagnosed with epilepsy. Again, the efficacy of zonisamide was defined as the percentage of patients that demonstrated a 50% or greater reduction in seizure frequency compared to the patient's seizure frequency before administration of zonisamide, to the total number of patients in each group. The mean doses were 5.47 ± 2.62 mg/kg per day in patients under 16 years, and 248.8 ± 102.4 mg per day in patients age 16 or older. The mean concentration was 14.62 ± 8.18 g/mL in patients under age 16, and 15.83 ± 8.98 g/mL in patients age 16 or older. The mean duration of zonisamide treatment was 334.5 ± 244.7 days.
Among 359 patients with partial epilepsies, effective control of seizures was achieved with zonisamide monotherapy in 79% of 99 newly-diagnosed patients with temporal lobe epilepsy, 84% of 243 with non-temporal lobe epilepsies, and 88% of 17 with unclassified partial epilepsies. Zonisamide monotherapy was effective in controlling seizures in 50-100% of 367 patients with newly-diagnosed S14 K. Yagi generalized and other undetermined epilepsies ( Table 4 ). The efficacy rates of zonisamide monotherapy by seizure type in 726 newly-diagnosed patients with partial or generalized seizures were also favorable (Table 5) .
Clinical experience at the National Epilepsy Center
A cohort of 50 patients with generalized epilepsies treated with zonisamide and 1 additional concomitant AED was studied. Of these patients, 6 and 27 had idiopathic and symptomatic generalized epilepsies, respectively; 2 had Lennox-Gastaut syndrome, 14 had West syndrome, and 1 had Doose syndrome. A further cohort of 19 patients with undetermined epilepsies and specific syndromes was studied. Of these, seven had refractory childhood grand mal seizures, five had severe myoclonic epilepsy in infancy, four had other undetermined epilepsy, two had familial essential myoclonic epilepsy, and one had mitochondrial encephalomyopathy with ragged-red fibers.
In both these cohorts, when zonisamide was administered alone or with one other AED for more than 6 months, seizure frequency was reduced by 50% or more for more than 6 months. All 14 children with West syndrome showed seizure control for 3-5 months on zonisamide monotherapy or zonisamide plus one other AED (mostly valproate). Four of these patients (two on monotherapy and two on zonisamide plus one other AED) had experienced complete freedom from seizures for more than 12 months.
Case study 1
Following is a case study of a 6-month-old boy with West syndrome treated with zonisamide. There were no abnormal findings in the first few months after birth. At age 5 months, it was noted that the baby's body twitched momentarily just as he was falling asleep. Two weeks later, seizures occurred in series. Each series consisted of 10-30 spasms and occurred 3-4 times per day. The electroencephalogram (EEG) showed hypsarrhythmia. Computerized axial tomography and magnetic resonance imaging revealed no specific findings. Vitamin B 6 (30-50 mg/kg per day) was administered for 1 week, but proved ineffective. Therefore, valproate was started and Vitamin B 6 was tapered off. Although the dose of valproate was increased up to 350 mg per day and correlated with serum concentrations of up to 137 g/mL, it had no effect on seizure occurrence. Consequently, zonisamide was started as adjunctive therapy and the incidence of seizures began to decrease. Once the dose of zonisamide was increased to 55 mg per day, the seizures completely disappeared. EEG also showed signs of marked improvement. The serum concentration of zonisamide was maintained between 12 and 16 g/mL. No further seizures have been observed during the past year of zonisamide.
Case study 2
Following is a case study of an 8-year-old girl diagnosed with Lennox-Gastaut syndrome treated with zonisamide. She had a history of myoclonic and tonic seizures at the age of 26 months. At age 5, she presented with atypical absence seizures. After treatment with valproate, all seizures disappeared. However, at age 8, tonic seizures recurred. Both before and at this time, serum concentration of valproate was 103 g/mL. EEG after seizure recurrence showed frequent slow spike-and-wave complexes and fast rhythm.
Valproate was discontinued and zonisamide initiated at a dose of 100 mg per day. After 1 month, tonic seizures ceased and EEG showed no epileptic discharges. The seizures were still controlled 19 months later and the patient had experienced no adverse reactions.
Case study 3
In this case study, a 14-month-old girl with symptomatic generalized epilepsy presented with a history of myoclonic seizures that developed at 1 year of age. Seizures occurred 20-30 times a day. EEG showed frequent generalized diffused poly-spikes. Sodium valproate at a dose of 400 mg daily was administered without effect. Phenytoin was added but no remarkable improvement was seen. Zonisamide was added at a dose of 70 mg per day, which was ineffective. The dose was increased to 120 mg per day, after which the seizures decreased and stopped. Valproate and phenytoin were then discontinued. Monotherapy with zonisamide was continued and the seizures disappeared with a serum concentration of 26-32 g/mL. The EEG returned to normal.
Conclusion
Because zonisamide is approved in Japan for use in monotherapy in children as well as adults, examination of data from pre-and postmarketing studies conducted in that country provides insight into the use of zonisamide in clinical practice.
Experience with zonisamide in Japan suggests that it has a broad spectrum of activity, demonstrating improvements in seizure rates across a range of epilepsy and seizure types in infants, children, and adults. Administered as monotherapy or in combination with one or more other AEDs, zonisamide consistently reduces the frequency of seizures by 50% or more, and offers long-term efficacy. Zonisamide is an important addition to the drugs available for the management of epilepsy.
